Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma)

被引:33
|
作者
Lenders, Nele [1 ,2 ,3 ]
McCormack, Ann [1 ,2 ]
机构
[1] Garvan Inst Med Res, Sydney, NSW, Australia
[2] Univ New South Wales, St Vincents Hosp, Dept Endocrinol, Sydney, NSW, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
关键词
Pituitary carcinomas; Non-functioning pituitary adenomas; Aggressive pituitary tumours; Metastases; Temozolomide; OF-THE-LITERATURE; RECEPTOR RADIONUCLIDE THERAPY; SILENT CORTICOTROPH ADENOMAS; LONG-TERM SURVIVAL; TEMOZOLOMIDE TREATMENT; RADIATION-THERAPY; CUSHING DISEASE; P53; EXPRESSION; CELL-CARCINOMA; TUMOR CELLS;
D O I
10.1007/s11102-017-0857-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.
引用
收藏
页码:217 / 229
页数:13
相关论文
共 50 条
  • [21] Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas
    Chanson, Philippe
    Dormoy, Alexandre
    Dekkers, Olaf M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (01) : D1 - D13
  • [22] The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)
    Yavropoulou, Maria P.
    Tsoli, Marina
    Barkas, Konstantinos
    Kaltsas, Gregory
    Grossman, Ashley
    ENDOCRINE-RELATED CANCER, 2020, 27 (10) : R375 - R390
  • [23] Diagnosis and management of prolactinomas and non-functioning pituitary adenomas
    Rogers, Angela
    Karavitaki, Niki
    Wass, John A. H.
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [24] Non-Functioning Pituitary Adenomas: A Single Center Experience
    Anagnostis, P.
    Adamidou, F.
    Polyzos, S. A.
    Efstathiadou, Z.
    Panagiotou, A.
    Kita, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (05) : 314 - 319
  • [25] Telomerase expression in clinically non-functioning pituitary adenomas
    Ogino, Liana Lumi
    Lamback, Elisa Baranski
    Guterres, Alexandro
    de Azeredo Lima, Carlos Henrique
    Henriques, Daniel Gomes
    Barbosa, Monique Alvares
    Silva, Debora Aparecida
    da Silva Camacho, Aline Helen
    Chimelli, Leila
    Kasuki, Leandro
    Gadelha, Monica R.
    ENDOCRINE, 2021, 72 (01) : 208 - 215
  • [26] Giant Non-Functioning Pituitary Adenomas: Treatment Considerations
    Solari, Domenico
    Cavallo, Luigi Maria
    Graziadio, Chiara
    Corvino, Sergio
    Bove, Ilaria
    Esposito, Felice
    Cappabianca, Paolo
    BRAIN SCIENCES, 2022, 12 (09)
  • [27] Are volume measurements of non-functioning pituitary adenomas reliable?
    Oystese, Kristin Astrid Berland
    Hisanawi, Sheren
    Zucknick, Manuela
    Bollerslev, Jens
    Ringstad, Geir
    ENDOCRINE, 2019, 63 (01) : 171 - 176
  • [28] Telomerase expression in clinically non-functioning pituitary adenomas
    Liana Lumi Ogino
    Elisa Baranski Lamback
    Alexandro Guterres
    Carlos Henrique de Azeredo Lima
    Daniel Gomes Henriques
    Monique Alvares Barbosa
    Débora Aparecida Silva
    Aline Helen da Silva Camacho
    Leila Chimelli
    Leandro Kasuki
    Mônica R. Gadelha
    Endocrine, 2021, 72 : 208 - 215
  • [29] A Review of Treatment with Cabergoline for Non-Functioning Pituitary Adenomas
    Papneja, Netee
    Caspar-Bell, Gudrun Martina
    Imran, Syed Ali
    Cooper, Paul Edward
    Van Uum, Stan
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [30] NON-FUNCTIONING PITUITARY ADENOMAS : A PLEA FOR AN EARLIER DIAGNOSIS
    Yvan, Zunon-Kipre
    Esperance, Broalet
    Landry, Drogba
    Aderehime, Haidara
    Herman, N'Da
    Vincent, Bazeze
    AFRICAN JOURNAL OF NEUROLOGICAL SCIENCES, 2007, 26 (02): : 83 - 94